Close Menu

Evogen

The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.

NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.

Evogen, a Lenexa, Kansas-based developer of molecular detection and diagnostic technologies, said this week that it has non-exclusively licensed its PCR probe technology to Focus Diagnostics, a Quest Diagnostics subsidiary.

NEW YORK (GenomeWeb News) – Evogen has granted Focus Diagnostics a license to incorporate Evogen's HyBeacons PCR probe technology into Focus' molecular diagnostic products and services, the firms announced today.

Lumora has appointed Jim Reid as chairman.

Cepheid said this week that its board of directors has elected John Bishop as chairman and Cristina Kepner as lead independent director.

Mari Baker is leaving Navigenics, Andrew von Eschenbach has joined a consulting firm, Jay Flatley takes a seat on Helixis' board, and more.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.